Survival in advanced melanoma

The results of BRIM-3, a phase III randomised, open-label, multicentre trial comparing BRAF inhibitor vemurafenib with standard chemotherapy (dacarbazine) in previously untreated patients with BRAF V600E-mutated melanoma

The results of BRIM-3, a phase III randomised, open-label, multicentre trial comparing BRAF inhibitor vemurafenib with standard chemotherapy (dacarbazine) in previously untreated patients with BRAF V600E-mutated melanoma were presented at the annual meeting of the American Society of Clinical Oncology in Chicago, Illinois.

The updated overall survival (OS) analysis had a 10-month median follow-up on vemurafenib. It looked at 675 patients with previously untreated, unresectable stage IIIC or IV metastatic melanoma who were BRAF V600E-mutation positive and were randomised to vemurafenib or dacarbazine. At 12 months, OS rates were 55% in patients who had received vemurafenib compared to 43% in dacarbazine recipients.

However, NICE has announced in its draft guidance that it is not recommending NHS use of vemurafenib owing to its high costs and uncertainties over its survival benefits.
Chapman PB, Hauschild A, Robert C et al. J Clin Oncol 30, 2012; (suppl; abstr 8502)


Read these next

Retinol and melanoma risk

Intake of high-dose (>1,200 microgram per day) retinol...

The increase in non-melanoma skin cancer

The increase in non-melanoma skin cancer

Sun-seeking behaviour is thought to be the main cause...

Computer-aided skin lesion analysis in melanoma

Computer-aided digital skin lesion analysis can improve...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases